Stocktoria
X4 Pharmaceuticals, Inc XFOR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2017-11-16
X4 Pharmaceuticals, Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $35.1M | $2.6M | $0 | $0 | $0 |
| R&D expense | $72.7M | $81.6M | $72.0M | $61.1M | $50.6M |
| Operating income | -$86.9M | -$36.4M | -$107.5M | -$87.6M | -$85.1M |
| Interest expense | — | — | $5.8M | $4.0M | $3.6M |
| Income tax | $41,000 | $310,000 | $78,000 | $28,000 | $17,000 |
| Net income | -$79.2M | -$37.5M | -$101.2M | -$93.9M | -$88.7M |
| EPS (diluted) | $-1.87 | $-5.59 | $-17.07 | $-1.52 | $-3.99 |
| Operating cash flow | -$85.6M | -$130.9M | -$96.5M | -$77.1M | -$70.9M |
| Free cash flow | — | -$131.2M | -$96.6M | -$77.2M | — |
| Cash & equivalents | $217.0M | $55.7M | $99.2M | $121.7M | $81.8M |
| Inventory | — | $2.8M | $0 | — | — |
| Total assets | $290.5M | $146.4M | $147.3M | $155.6M | $117.2M |
| Total liabilities | $104.2M | $124.3M | $96.2M | $81.5M | $52.8M |
| Shareholders' equity | $186.3M | $22.1M | $51.1M | $74.1M | $64.4M |
Source: SEC EDGAR filings · CIK 0001501697 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.